This website uses cookies to improve the site and user experience. By continuing to browse this site, you agree to accept our use of cookies. For more information, please review our Cookies Policy.

Take the next step in the treatment of high-risk classical Hodgkin lymphoma in children with ADCETRIS

ADCETRIS, in combination with a chemotherapy regimen called AVEPC (doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide), is FDA approved to treat children 2 years of age and older with previously untreated high-risk classical Hodgkin lymphoma.

In a clinical trial called AHOD1331, ADCETRIS plus AVEPC reduced the risk of cancer progression, relapse, a separate cancer diagnosis, or death by 59% when compared to ABVEPC chemotherapy alone (doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide) in pediatric patients with previously untreated high-risk classical Hodgkin lymphoma.

92% of patients treated with ADCETRIS plus AVEPC did not experience cancer progression, relapse, a separate cancer diagnosis, or death compared to 83% of those treated with ABVEPC alone.

See study results

How does ADCETRIS work?

ADCETRIS is not like traditional chemotherapy. It is an antibody drug conjugate made up of 3 parts:
an antibody, a drug, and a linker.

ADCETRIS attaching to cell via CD30 protein.

Step 1

ADCETRIS aims to attach to cells that have a protein on their surface called CD30.

ADCETRIS is released inside the cell.

Step 2

Once attached, ADCETRIS is brought into the cell and released.

Cell death.

Step 3

The drug stops the cell from being able to grow and divide, causing the cell to die.

CD30 is found on classical Hodgkin lymphoma cells and not commonly found on healthy cells.
Even though ADCETRIS is a CD30-directed therapy, it can still harm normal cells and cause side effects. Bring any questions about possible side effects to a doctor.

Results from the AHOD1331 clinical study

Study results

Side effects

In the study conducted by the Children’s Oncology Group network, ADCETRIS plus AVEPC chemotherapy was compared to traditional ABVEPC chemotherapy in pediatric patients with previously untreated high-risk classical Hodgkin lymphoma:

  • 298 pediatric patients received ADCETRIS plus AVEPC every 3 weeks for up to 5 cycles
  • 289 pediatric patients received ABVEPC every 3 weeks for up to 5 cycles

High risk was defined as Ann Arbor Stage 2B with bulk disease, Stage 3B, Stage 4A, and Stage 4B.

Main study results

Results used to support the FDA-approved use of ADCETRIS plus AVEPC. The average follow-up time for all patients was just over 3 years. Patients ranged in age from 3 to 21 years; the average age was 15.

ADCETRIS plus AVEPC offered pediatric patients more time without cancer progression, relapse, a separate cancer diagnosis, or death.

Compared to those treated with traditional ABVEPC chemotherapy, pediatric patients treated with ADCETRIS plus AVEPC had a:

59%REDUCED RISK OF

  • Cancer growing or spreading
  • Cancer coming back
  • Development of separate cancer diagnosis
  • Death

At 3 years, approximately 10% more people did not have their cancer grow or spread, have their cancer come back, receive a separate cancer diagnosis, or die when treated with ADCETRIS plus AVEPC (92% total) when compared to those treated with traditional ABVEPC (83% total).

What to expect during treatment with ADCETRIS

How ADCETRIS is given

ADCETRIS is given as an intravenous (IV) infusion (directly into the vein), at the doctor’s office or clinic.

Patients will receive ADCETRIS with chemotherapy every 3 weeks for up to 5 treatments.

The ADCETRIS infusion takes about 30 minutes. Additional time is needed for AVEPC chemotherapy infusions. The doctor may ask patients to come to the office early to prepare and stay afterward for monitoring.

Before starting treatment, tell the doctor about the following:

  • All medical conditions.
  • Current medications, including over-the-counter drugs, and any herbal or vitamin supplements. ADCETRIS can interact with some types of drugs.
  • If a patient or their partner is pregnant, may become pregnant, or plan to become pregnant. Do not receive ADCETRIS while pregnant, and do not attempt to become pregnant for 6 months after the last ADCETRIS dose.
  • If a patient or their partner is breastfeeding. Because of the potential for serious adverse reactions in a breastfed child from ADCETRIS, breastfeeding is not recommended during treatment.

Questions about ADCETRIS

It's important to share concerns about ADCETRIS treatment with a doctor. The questions below can help guide the conversation.

  • How does ADCETRIS help treat classical Hodgkin lymphoma?
  • What are the benefits and risks of ADCETRIS?
  • What are the most common side effects of ADCETRIS?
  • What are the chances of a serious side effect like progressive multifocal leukoencephalopathy (PML)?
  • What steps should be taken if a patient experiences side effects?
  • Will treatment need to stop due to side effects?
  • Will ADCETRIS interfere with other medications?
  • How will treatment interrupt day-to-day life?

Downloadable resources

The resources below may be helpful during ADCETRIS treatment

Important Facts

Download (English)
Download (Spanish)

Full Prescribing Information

Download (English)
Download (Spanish)

ADCETRIS patient brochure

Download (English)
Download (Spanish)

Helpful links*

Connect with caregivers and patients in the cancer support community

Dedicated to funding research, finding cures, and ensuring access to treatments for patients. The Leukemia & Lymphoma Society (LLS) is committed to providing information, resources, and support to those affected by blood cancers.

lls.org

Devoted to improving care through patient education and support services and improving outcomes through investment in the most promising lymphoma research.

lymphoma.org

Provides case management, counseling, support groups, education, publications, and financial and co-payment assistance.

cancercare.org

Offers a global network of support that is available online and at community-based centers and hospitals.

cancersupportcommunity.org

Provides information, support, referrals, and services to cancer patients to help protect their individual reproductive and parenthood goals.

allianceforfertilitypreservation.org

Apps to help manage care*

From cost to resources, supporting patients every step of the way

Seagen Secure® logo.

The Seagen Secure® patient assistance program is designed to help patients begin their prescribed ADCETRIS treatment. If eligible and enrolled, a dedicated Oncology Access Advocate will provide comprehensive, personalized support, including:

  • Confirmation of insurance coverage
  • Evaluating out of pocket costs and available copay options
  • Help with alternative financial support if ADCETRIS isn’t affordable*

Talk to a healthcare provider or Call 855-4SECURE (855-473-2873) to
learn how to enroll in Seagen Secure®.

Visit the website

Information provided by Seagen Secure is not intended to be a substitute for a healthcare provider. Discuss any questions about classical Hodgkin lymphoma and treatment with the patient's healthcare team.

*Financial support may be provided through foundation referral. Seagen does not guarantee that enrollment will result in coverage and/or reimbursement.

Important Safety Information

What is the most important information I should know about ADCETRIS?

  • PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML): Patients treated with ADCETRIS can have a rare, serious brain infection called PML that can lead to death. Tell your doctor immediately if you have mood or behavior changes, confusion, problems in thinking or loss of memory, changes in vision, speech, or walking, or decreased strength or weakness on one side of the body. PML may also be caused by prior treatments or diseases that weakened your immune system.
  • Do not take ADCETRIS if you are receiving bleomycin

What are the other possible serious side effects of ADCETRIS?

  • Nerve damage (peripheral neuropathy). Tell your doctor if you have any numbness or tingling in your hands or feet or any muscle weakness.
  • Allergic and infusion reactions. Tell your doctor if you experience symptoms of fever, chills, rash, or breathing problems within 24 hours of infusion. If you have a reaction, you may be given medicines before your ADCETRIS treatment.
  • Blood problems. Serious cases, including death, of fever with a low number of white blood cells have occurred with ADCETRIS. Serious cases of a low number of white blood cells, a low number of platelets, or a low number of red blood cells can occur.

    Your doctor will do blood tests to check your blood cell levels during ADCETRIS treatment. Your doctor may give you a medicine called G-CSF. Tell your doctor if you have a fever of 100.5°F or higher, chills, cough, or pain when you urinate.

  • Infections caused by bacteria, fungi, or viruses have been reported.
  • Tumor lysis syndrome is caused by the fast breakdown of cancer cells. Your doctor will monitor you for symptoms.
  • Patients with severe kidney disease or moderate or severe liver disease may have more side effects and deaths than patients without kidney or liver problems.
  • Liver problems. Serious liver problems, including death, can occur. Tell your doctor if you feel tired, do not feel like eating, have upper stomach pain, dark urine, or yellow skin and eyes (jaundice).
  • Lung problems. Serious lung problems, including death, can occur. Tell your doctor if you have a new cough, a cough that gets worse, or feel out of breath.
  • Skin problems called Stevens-Johnson syndrome and toxic epidermal necrolysis can happen. Tell your doctor if you have rash, hives, sores in your mouth, or blistering or peeling skin.
  • Gastrointestinal (GI) problems. Serious cases, including death, related to the pancreas, stomach, intestine, and colon can happen. If you have lymphoma that involves your stomach or intestine, you could have a higher risk of GI problems. Tell your doctor if you have severe stomach pain, chills, fever, nausea, vomiting, or diarrhea.
  • High blood sugar. Your doctor will test your blood during ADCETRIS treatment. Tell your doctor if you need to urinate more often than usual, are very thirsty, or have blurry vision.

The most common side effects in any study of ADCETRIS include:

  • nerve damage (peripheral neuropathy)
  • feeling tired
  • nausea
  • diarrhea
  • a low number of white blood cells
  • infection in the nose or sinuses
  • fever
  • constipation
  • vomiting
  • hair loss
  • weight loss
  • upper stomach pain
  • a low number of red blood cells
  • sores or swelling in the mouth and/or in the digestive tract
  • decrease in platelets
  • fever with a low number of white blood cells

These are not all the possible side effects of ADCETRIS. Tell your doctor about any side effect that bothers you or does not go away. If you have certain side effects, your doctor may lower your dose, delay, or stop your ADCETRIS treatment.

What should I tell my doctor before I start treatment with ADCETRIS?

  • All your medical conditions, including if you have kidney, liver, or lung problems, an infection, or diabetes.
  • If you are pregnant or plan to become pregnant. ADCETRIS may harm your unborn baby. Females who are able to become pregnant: Your doctor should give you a pregnancy test before starting ADCETRIS treatment. You should use effective birth control during ADCETRIS treatment and for 6 months after your last dose of ADCETRIS. Tell your doctor right away if you become pregnant or think you are pregnant during ADCETRIS treatment. Men with female partners who can get pregnant should use effective birth control during ADCETRIS treatment and for 6 months after the last dose.
  • If you are breastfeeding or plan to breastfeed. Do not breastfeed during ADCETRIS treatment.
  • All the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. ADCETRIS and certain other medicines can affect each other.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/Safety/MedWatch or call 1-800-FDA-1088.

Please see Important Facts about ADCETRIS, including IMPORTANT WARNING.

What is ADCETRIS?

ADCETRIS is a prescription medicine directed against the CD30 protein. It is used to treat:

  • Adults with previously untreated Stage 3 or 4 classical Hodgkin lymphoma, in combination with chemotherapy (Adriamycin, vinblastine, and dacarbazine)
  • Children 2 years of age and older with previously untreated high risk classical Hodgkin lymphoma, in combination with chemotherapy (doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide)
  • Adults with classical Hodgkin lymphoma at high risk of coming back or becoming worse after a stem cell transplant
  • Adults with classical Hodgkin lymphoma after a stem cell transplant fails or after at least 2 chemotherapy treatments fail and stem cell transplant is not an option
  • Adults with previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphomas, including angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphomas not otherwise specified, in combination with chemotherapy (cyclophosphamide, doxorubicin, and prednisone)
  • Adults with systemic anaplastic large cell lymphoma after at least 1 combination chemotherapy treatment fails
  • Adults with primary cutaneous anaplastic large cell lymphoma or CD30-expressing mycosis fungoides after systemic therapy (drugs that spread throughout the body)

Important Safety Information

What is the most important information I should know about ADCETRIS?

  • PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML): Patients treated with ADCETRIS can have a rare, serious brain infection called PML that can lead to death. Tell your doctor immediately if you have mood or behavior changes, confusion, problems in thinking or loss of memory, changes in vision, speech, or walking, or decreased strength or weakness on one side of the body. PML may also be caused by prior treatments or diseases that weakened your immune system.
  • Do not take ADCETRIS if you are receiving bleomycin

What are the other possible serious side effects of ADCETRIS?

  • Nerve damage (peripheral neuropathy). Tell your doctor if you have any numbness or tingling in your hands or feet or any muscle weakness.
  • Allergic and infusion reactions. Tell your doctor if you experience symptoms of fever, chills, rash, or breathing problems within 24 hours of infusion. If you have a reaction, you may be given medicines before your ADCETRIS treatment.
  • Blood problems. Serious cases, including death, of fever with a low number of white blood cells have occurred with ADCETRIS. Serious cases of a low number of white blood cells, a low number of platelets, or a low number of red blood cells can occur.

    Your doctor will do blood tests to check your blood cell levels during ADCETRIS treatment. Your doctor may give you a medicine called G-CSF. Tell your doctor if you have a fever of 100.5°F or higher, chills, cough, or pain when you urinate.

  • Infections caused by bacteria, fungi, or viruses have been reported.
  • Tumor lysis syndrome is caused by the fast breakdown of cancer cells. Your doctor will monitor you for symptoms.
  • Patients with severe kidney disease or moderate or severe liver disease may have more side effects and deaths than patients without kidney or liver problems.
  • Liver problems. Serious liver problems, including death, can occur. Tell your doctor if you feel tired, do not feel like eating, have upper stomach pain, dark urine, or yellow skin and eyes (jaundice).
  • Lung problems. Serious lung problems, including death, can occur. Tell your doctor if you have a new cough, a cough that gets worse, or feel out of breath.
  • Skin problems called Stevens-Johnson syndrome and toxic epidermal necrolysis can happen. Tell your doctor if you have rash, hives, sores in your mouth, or blistering or peeling skin.
  • Gastrointestinal (GI) problems. Serious cases, including death, related to the pancreas, stomach, intestine, and colon can happen. If you have lymphoma that involves your stomach or intestine, you could have a higher risk of GI problems. Tell your doctor if you have severe stomach pain, chills, fever, nausea, vomiting, or diarrhea.
  • High blood sugar. Your doctor will test your blood during ADCETRIS treatment. Tell your doctor if you need to urinate more often than usual, are very thirsty, or have blurry vision.

The most common side effects in any study of ADCETRIS include:

  • nerve damage (peripheral neuropathy)
  • feeling tired
  • nausea
  • diarrhea
  • a low number of white blood cells
  • infection in the nose or sinuses
  • fever
  • constipation
  • vomiting
  • hair loss
  • weight loss
  • upper stomach pain
  • a low number of red blood cells
  • sores or swelling in the mouth and/or in the digestive tract
  • decrease in platelets
  • fever with a low number of white blood cells

These are not all the possible side effects of ADCETRIS. Tell your doctor about any side effect that bothers you or does not go away. If you have certain side effects, your doctor may lower your dose, delay, or stop your ADCETRIS treatment.

What should I tell my doctor before I start treatment with ADCETRIS?

  • All your medical conditions, including if you have kidney, liver, or lung problems, an infection, or diabetes.
  • If you are pregnant or plan to become pregnant. ADCETRIS may harm your unborn baby. Females who are able to become pregnant: Your doctor should give you a pregnancy test before starting ADCETRIS treatment. You should use effective birth control during ADCETRIS treatment and for 6 months after your last dose of ADCETRIS. Tell your doctor right away if you become pregnant or think you are pregnant during ADCETRIS treatment. Men with female partners who can get pregnant should use effective birth control during ADCETRIS treatment and for 6 months after the last dose.
  • If you are breastfeeding or plan to breastfeed. Do not breastfeed during ADCETRIS treatment.
  • All the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. ADCETRIS and certain other medicines can affect each other.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/Safety/MedWatch or call 1-800-FDA-1088.

Please see Important Facts about ADCETRIS, including IMPORTANT WARNING.

What is ADCETRIS?

ADCETRIS is a prescription medicine directed against the CD30 protein. It is used to treat:

  • Adults with previously untreated Stage 3 or 4 classical Hodgkin lymphoma, in combination with chemotherapy (Adriamycin, vinblastine, and dacarbazine)
  • Children 2 years of age and older with previously untreated high risk classical Hodgkin lymphoma, in combination with chemotherapy (doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide)
  • Adults with classical Hodgkin lymphoma at high risk of coming back or becoming worse after a stem cell transplant
  • Adults with classical Hodgkin lymphoma after a stem cell transplant fails or after at least 2 chemotherapy treatments fail and stem cell transplant is not an option
  • Adults with previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphomas, including angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphomas not otherwise specified, in combination with chemotherapy (cyclophosphamide, doxorubicin, and prednisone)
  • Adults with systemic anaplastic large cell lymphoma after at least 1 combination chemotherapy treatment fails
  • Adults with primary cutaneous anaplastic large cell lymphoma or CD30-expressing mycosis fungoides after systemic therapy (drugs that spread throughout the body)

This website is intended for US residents 18 years of age or older.

ADCETRIS and its logo, Seagen Secure and its logo, and Seagen and , are US registered trademarks of Seagen Inc. All other trademarks, trade names,
and service marks referred to herein are the property of their respective owners. Seagen is not associated with or sponsored by such trademark owners.

© 2023 Seagen Inc., Bothell, WA 98021

All rights reserved    US-BVP-22-398-MT